We adopt a de-risked, dual-pathway business model to maximize the commercial value of our solution platforms.
This model combines
(i)product partnerships for advancing our in-house pipeline through licensing, co-development, or commercialization, and
(ii)platform partnerships offering delivery systems, lipid libraries, and discovery solutions to external partners.
Our dual-pathway business model is strategically structured to help achieve self-sufficiency, with revenues generated from our platform business expected to support the ongoing research and development of our pipeline assets.
